FIELD: medicine; biotechnology.
SUBSTANCE: group of inventions relates to biotechnology and medicine, in particular to use of a pharmaceutical composition for treating an elderly human patient with solid cancer or a human patient at the terminal stage of solid cancer or to create remission conditions in an elderly human patient with solid cancer or in a human patient at the terminal stage of solid cancer. Composition contains as active ingredient 10 mg (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or its pharmacologically acceptable salt. Composition is administered to the patient once a day. Said elderly human patient represents person of 70 years or older and has a neutrophil count to lymphocyte count in peripheral blood 4 or higher and/or has a ratio of thrombocyte count to lymphocyte count in peripheral blood 1.5 or higher. Also disclosed are a combination drug and a kit containing said pharmaceutical composition and an anticancer agent and/or a molecular-targeted drug.
EFFECT: invention enables treating elderly patients with solid cancer and patients at the terminal stage of solid cancer with fewer side effects in order to improve and maintain quality of life and prolong life.
5 cl, 20 dwg, 5 tbl, 15 ex
